Pure Global

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder - Trial NCT06267846

Access comprehensive clinical trial information for NCT06267846 through Pure Global AI's free database. This Phase 2 trial is sponsored by Neurocrine Biosciences and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06267846
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06267846
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder

Study Focus

Major Depressive Disorder

NBI-1070770

Interventional

drug

Sponsor & Location

Neurocrine Biosciences

Rogers,Lemon Grove,Long Beach,Hollywood,Gaithersburg, United States of America

Timeline & Enrollment

Phase 2

Mar 01, 2024

Dec 01, 2025

72 participants

Primary Outcome

Change in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5

Summary

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on
 improving symptoms of depression in participants with major depressive disorder (MDD).

ICD-10 Classifications

Recurrent depressive disorder
Recurrent depressive disorder, unspecified
Depressive conduct disorder
Other recurrent depressive disorders
Recurrent depressive disorder, current episode moderate

Data Source

ClinicalTrials.gov

NCT06267846

Non-Device Trial